Verenigde Staten - Engels - NLM (National Library of Medicine)

advanced pharmaceutical technology, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 50 mg - estradiol is indicated in the treatment of: 1. estrogen deficiency in hysterectomized women. (there is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. atrophic vaginitis. 3. kraurosis vulvae. 4. female hypogonadism. 5. female castration. 6. primary ovarian failure. 7. breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. postpartum breast engorgement- althoughestrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies hve demonstrated that the incidence of significapainful engorgementin patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 estradiol has not been shown to be effective for any purpose durig pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women (or men) with any of the following conditions: 1. known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2. known or suspected estrogen-dependant neoplasia. 3. known or suspected pregnancy (see boxed warning). 4. undiagnosed abnormal genital bleeding. 5. active thrombophlebitis or thromboembolic disorders. 6. apast history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast prostatic malignancy).

Verenigde Staten - Engels - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the m

Verenigde Staten - Engels - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

cardinal health - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

avera mckennan hospital - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

direct rx - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets usp are indicated in the: treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology, clinical studies.) the mainstays for decreasing the risk of

Verenigde Staten - Engels - NLM (National Library of Medicine)

noven therapeutics, llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 0.05 mg in 1 d - combipatch is indicated in a woman with a uterus for: - treatment of moderate to severe vasomotor symptoms due to menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. combipatch is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen-dependent neoplasia. - active dvt, pe, or history of these conditions. - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema or hypersensitivity with combipatch. - known liver impairment or disease. - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders. - known or suspected pregnancy. combipatch (käm-bē `pach) (estradiol/norethindrone acetate transdermal system) step 1. pick the days you will change your combipatch. - you will need to change your patch every 3 to 4 days (twice weekly). step 2. remove combipatch from the pouch. - tear open the protective pouch at the slit (do not use scissors) and remove the patch. see figure a. - the pouch should not be opened until you are ready to put the patch on. step 3. remove the adhesive liner. - peel off one side of the protective liner. see figure b. - do not touch the sticky part of the patch with your fingers. see figure b. step 4. placing the combipatch on your skin. - put the sticky side of the patch on the lower abdomen (below the panty line). see figure c. - peel off the second side of the protective liner. see figure c. - press the patch firmly in place with your hand for about 10 seconds. see figure d. note: - avoid the waistline, since clothing and belts may cause the combipatch to be rubbed off. - do not apply the combipatch to or near your breasts. - only apply the combipatch to skin that is clean, dry, and free of any powder, oil, or lotion. - you should not apply the combipatch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy). step 5. press the combipatch firmly onto your skin. - rub the edges of the combipatch with your fingers to make sure that it will stick to your skin. see figure e. note: - bathing, swimming, or showering will not affect the combipatch. - once in place, the patch should not be exposed to the sun for prolonged periods of time. - if your combipatch falls off reapply it. if you cannot reapply the combipatch, apply a new combipatch to another area (see figures c , d and e) and continue to follow your original placement schedule. - if you stop using your combipatch or forget to apply a new combipatch as scheduled you may have spotting, or bleeding, and your symptoms may come back. step 6. throwing away your used combipatch. - when it is time to change your combipatch, remove the old combipatch before you apply a new one. - to throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash. used patches should not be flushed in the toilet. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by: noven pharmaceuticals inc. miami, fl 33186 distributed by: noven therapeutics, llc miami, fl 33186 for more information call 1-800-455-8070 or visit www.combipatch.com. © 2024 noven pharmaceuticals, inc. 102538-5 02/2024

Verenigde Staten - Engels - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for d

Verenigde Staten - Engels - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for d

Verenigde Staten - Engels - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for d